A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
By J. Hecht, Edith Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad, D. Spigel, John L. Marshall, A. Cohn, D. McCollum, P. Stella and 3 more. Journal of Clinical Oncology, 2009
859 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/2bc1fa8f5326f685e31f92811ad7383692ad1bf5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Anna Goldenberg
- Benjamin Haibe-Kains
- P. Smirnov
- Ladislav Rampášek
- Z. Safikhani
- George Adam
Citations in the corpus
- Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. (2010, neutral): “C Overall BCLC C 45 (40) 18 (45) 11 (28) 3.”
- Machine learning approaches to drug response prediction: challenges and recent progress (2020, background): “For example, Hecht et al. 65 performed a clinical trial for metastatic colorectal cancer (mCRC) patients involving the targeted compound bevacizumab, either oxaliplatin or irinotecan as a chemotherapeutic agent, and an optional addition of a human antibody panitumumab.”